“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Lamotrigine - Xr (Lamictal)

Trade Name : LAMICTAL

GlaxoSmithKline LLC

TABLET, FILM COATED, EXTENDED RELEASE

Strength 25 mg/1

LAMOTRIGINE Decreased Central Nervous System Disorganized Electrical Activity [PE],Mood Stabilizer [EPC],Anti-epileptic Agent [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Lamotrigine - Xr (Lamictal) which is also known as LAMICTAL and Manufactured by GlaxoSmithKline LLC. It is available in strength of 25 mg/1 per ml. Read more

Lamotrigine - Xr (Lamictal) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • No data
  • LAMICTAL XR can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive immediate-release lamotrigine, there was 1 rash-related death. LAMICTAL XR is not approved for patients younger than 13 years. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.
  • The risk of serious rash caused by treatment with LAMICTAL XR is not expected to differ from that with immediate-release lamotrigine. However, the relatively limited treatment experience with LAMICTAL XR makes it difficult to characterize the frequency and risk of serious rashes caused by treatment with LAMICTAL XR.
  • Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by LAMICTAL XR. There are suggestions, yet to be proven, that the risk of rash may also be increased by (1) coadministration of LAMICTAL XR with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of LAMICTAL XR, or (3) exceeding the recommended dose escalation for LAMICTAL XR. However, cases have occurred in the absence of these factors.
  • Nearly all cases of life-threatening rashes caused by immediate-release lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.
  • Although benign rashes are also caused by LAMICTAL XR, it is not possible to predict reliably which rashes will prove to be serious or life threatening. Accordingly, LAMICTAL XR should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug related. Discontinuation of treatment may not prevent a rash from becoming life threatening or permanently disabling or disfiguring .
  • WARNING: SERIOUS SKIN RASHES
  • See full prescribing information for complete boxed warning.
  • Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:
  • Benign rashes are also caused by lamotrigine; however, it is not possible to predict which rashes will prove to be serious or life threatening. LAMICTAL XR should be discontinued at the first sign of rash, unless the rash is clearly not drug related. ()
  • LAMICTALu00a0XR is indicated for:
  • Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. ()
  • LAMICTAL XR extended-release tablets are taken once daily, with or without food. Tablets must be swallowed whole and must not be chewed, crushed, or divided.
  • 2.2n- 2.3
  • Arrayn- Array
  • 2.1n- 5.1
  • 2.1n- 5.8
  • 2.1n- 5.9
  • 25-mg, yellow with white center, round, biconvex, film-coated tablets printed with u201cLAMICTALu201d and u201cXR 25.u201d
  • 50-mg, green with white center, round, biconvex, film-coated tablets printed with u201cLAMICTALu201d and u201cXR 50.u201d
  • 100-mg, orange with white center, round, biconvex, film-coated tablets printed with u201cLAMICTALu201d and u201cXR 100.u201d
  • 200-mg, blue with white center, round, biconvex, film-coated tablets printed with u201cLAMICTALu201d and u201cXR 200.u201d
  • 250-mg, purple with white center, caplet-shaped, film-coated tablets printed with u201cLAMICTALu201d and u201cXR 250.u201d
  • 300-mg, gray with white center, caplet-shaped, film-coated tablets printed with u201cLAMICTALu201d and u201cXR 300.u201d
  • Extended-release tablets: 25u00a0mg, 50u00a0mg, 100u00a0mg, 200u00a0mg, 250 mg, and 300u00a0mg. (, )
  • LAMICTAL XR is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients .
  • Hypersensitivity to the drug or its ingredients. (, )
  • No data
  • Boxed Warningn- 5.1
  • 5.7n- 16n- 17
  • The following serious adverse reactions are described in more detail in the section of the labeling:
  • To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or.
  • Significant drug interactions with lamotrigine are summarized in this section. Additional details of these drug interaction studies, which were conducted using immediate-release lamotrigine, are provided in the Clinical Pharmacology section .
  • Uridine 5u00b4-diphospho-glucuronyl transferases (UGT) have been identified as the enzymes responsible for metabolism of lamotrigine. Drugs that induce or inhibit glucuronidation may, therefore, affect the apparent clearance of lamotrigine. Strong or moderate inducers of the cytochrome P450 3A4 (CYP3A4) enzyme, which are also known to induce UGT, may also enhance the metabolism of lamotrigine.
  • Those drugs that have been demonstrated to have a clinically significant impact on lamotrigine metabolism are outlined in Table 13. Specific dosing guidance for these drugs is provided in the Dosage and Administration section .
  • Effect of LAMICTAL XR on Organic Cationic Transporter 2 Substrates
  • Lamotrigine is an inhibitor of renal tubular secretion via organic cationic transporter 2 (OCT2) proteins . This may result in increased plasma levels of certain drugs that are substantially excreted via this route. Coadministration of LAMICTAL XR with OCT2 substrates with a narrow therapeutic index (e.g., dofetilide) is not recommended.
  • 7n- 12.3
  • 7n- 12.3
  • 7n- 12.3
  • 7n- 12.3
  • 7n- 12.3
  • No data
  • 2.1n- 8.6
  • 2.1n- 8.7
  • No data
  • LAMICTALu00a0XR (lamotrigine), an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigineu2019s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)--triazine, its molecular formula is CHNCl, and its molecular weight is 256.09. Lamotrigine is a white to pale cream-colored powder and has a pK of 5.7. Lamotrigine is very slightly soluble in water (0.17u00a0mg/mL at 25u00b0C) and slightly soluble in 0.1u00a0M HCl (4.1u00a0mg/mL at 25u00b0C). The structural formula is:
  • LAMICTAL XR extended-release tablets are supplied for oral administration as 25-mg (yellow with white center), 50-mg (green with white center), 100-mg (orange with white center), 200-mg (blue with white center), 250-mg (purple with white center), and 300-mg (gray with white center) tablets. Each tablet contains the labeled amount of lamotrigine and the following inactive ingredients: glycerol monostearate, hypromellose, lactose monohydrate; magnesium stearate; methacrylic acid copolymer dispersion, polyethylene glycol 400, polysorbate 80, silicon dioxide (25- and 50-mg tablets only), titanium dioxide, triethyl citrate, carmine (250-mg tablet only), iron oxide black (50-, 250-, and 300-mg tablets only), iron oxide yellow (25-, 50-, and 100-mg tablets only), iron oxide red (100-mg tablet only), FD&C Blue No. 2 Aluminum Lake (200- and 250-mg tablets only). Tablets are printed with edible black ink.
  • LAMICTALu00a0XR extended-release tablets contain a modified-release eroding formulation as the core. The tablets are coated with a clear enteric coat and have an aperture drilled through the coats on both faces of the tablet (DiffCORE) to enable a controlled release of drug in the acidic environment of the stomach. The combination of this and the modified-release core are designed to control the dissolution rate of lamotrigine over a period of approximately 12 to 15 hours, leading to a gradual increase in serum lamotrigine levels.
  • No data
  • No evidence of carcinogenicity was seen in mice or rats following oral administration of lamotrigine for up to 2 years at doses up to 30 mg/kg/day and 10 to 15 mg/kg/ day, respectively. The highest doses tested are less than the human dose of 400 mg/day on a body surface area (mg/m) basis.
  • Lamotrigine was negative in in vitro gene mutation (Ames and mouse lymphoma ) assays and in clastogenicity (in vitro human lymphocyte and in vivo rat bone marrow) assays.
  • No evidence of impaired fertility was detected in rats given oral doses of lamotrigine up to 20 mg/kg/day. The highest dose tested is less than the human dose of 400 mg/day on a mg/m basis.
  • No data
  • 1. French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. . 2010; 51(10):1936-1943.
  • LAMICTALu00a0XR (lamotrigine) extended-release tablets
  • 25-mg, yellow with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 25u201d, unit-of-use bottles of 30 with orange caps (NDC 0173-0754-00).
  • 50-mg, green with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 50u201d, unit-of-use bottles of 30 with orange caps (NDC 0173-0755-00).
  • 100-mg, orange with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 100u201d, unit-of-use bottles of 30 with orange caps (NDC 0173-0756-00).
  • 200-mg, blue with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 200u201d, unit-of-use bottles of 30 with orange caps (NDC 0173-0757-00).
  • 250-mg, purple with a white center, caplet-shaped, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 250u201d, unit-of-use bottles of 30 with orange caps (NDC 0173-0781-00).
  • 300-mg, gray with a white center, caplet-shaped, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 300u201d, unit-of-use bottles of 30 with orange caps (NDC 0173-0761-00).
  • LAMICTALu00a0XR (lamotrigine) Patient Titration Kit for Patients Taking Valproate (Blue XR Kit)
  • 25-mg, yellow with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 25u201d and 50u00a0mg, green with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 50u201d; blister pack of 21/25-mg tablets and 7/50-mg tablets (NDC 0173-0758-00).
  • LAMICTALu00a0XR (lamotrigine) Patient Titration Kit for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone, and Not Taking Valproate (Green XR Kit)
  • 50-mg, green with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 50u201d; 100u00a0mg, orange with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 100u201d; and 200u00a0mg, blue with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 200u201d; blister pack of 14/50-mg tablets, 14/100-mg tablets, and 7/200-mg tablets (NDC 0173-0759-00).
  • LAMICTALu00a0XR (lamotrigine) Patient Titration Kit for Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate (Orange XR Kit)
  • 25-mg, yellow with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 25u201d; 50u00a0mg, green with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 50u201d; and 100u00a0mg, orange with a white center, round, biconvex, film-coated tablets printed on one face in black ink with u201cLAMICTALu201d and u201cXR 100u201d; blister pack of 14/25-mg tablets, 14/50-mg tablets, and 7/100-mg tablets (NDC 0173-0760-00).
  • Storage
  • Store at 25u00b0C (77u00b0F); excursions permitted to 15u00b0C to 30u00b0C (59u00b0F to 86u00b0F) [see USP Controlled Room Temperature].
  • Advise the patient to read the FDA-approved patient labeling (Medication Guide).
  • Rash
  • Prior to initiation of treatment with LAMICTALu00a0XR, inform patients that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and instruct them to report any such occurrence to their healthcare providers immediately.
  • Hemophagocytic Lymphohistiocytosis
  • Prior to initiation of treatment with LAMICTAL XR, inform patients that excessive immune activation may occur with LAMICTAL XR and that they should report signs or symptoms such as fever, rash, or lymphadenopathy to a healthcare provider immediately.
  • Multiorgan Hypersensitivity Reactions, Blood Dyscrasias, and Organ Failure
  • Inform patients that multiorgan hypersensitivity reactions and acute multiorgan failure may occur with LAMICTAL XR. Isolated organ failure or isolated blood dyscrasias without evidence of multiorgan hypersensitivity may also occur. Instruct patients to contact their healthcare providers immediately if they experience any signs or symptoms of these conditions n
  • Suicidal Thinking and Behavior
  • Inform patients, their caregivers, and families that AEDs, including LAMICTAL XR, may increase the risk of suicidal thoughts and behavior. Instruct them to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior or thoughts about self-harm. Instruct them to immediately report behaviors of concern to their healthcare providers.
  • Worsening of Seizures
  • Instruct patients to notify their healthcare providers if worsening of seizure control occurs.
  • Central Nervous System Adverse Effects
  • Inform patients that LAMICTALu00a0XR may cause dizziness, somnolence, and other symptoms and signs of central nervous system depression. Accordingly, instruct them neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on LAMICTALu00a0XR to gauge whether or not it adversely affects their mental and/or motor performance.
  • Pregnancy and Nursing
  • Instruct patients to notify their healthcare providers if they become pregnant or intend to become pregnant during therapy and if they intend to breastfeed or are breastfeeding an infant.
  • Encourage patients to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 .
  • Inform patients who intend to breastfeed that LAMICTAL XR is present in breast milk and advise them to monitor their child for potential adverse effects of this drug. Discuss the benefits and risks of continuing breastfeeding.
  • Oral Contraceptive Use
  • Instruct women to notify their healthcare providers if they plan to start or stop use of oral contraceptives or other female hormonal preparations. Starting estrogen-containing oral contraceptives may significantly decrease lamotrigine plasma levels and stopping estrogen-containing oral contraceptives (including the pill-free week) may significantly increase lamotrigine plasma levels . Also instruct women to promptly notify their healthcare providers if they experience adverse reactions or changes in menstrual pattern (e.g., break-through bleeding) while receiving LAMICTALu00a0XR in combination with these medications.
  • Discontinuing LAMICTALu00a0XR
  • Instruct patients to notify their healthcare providers if they stop taking LAMICTALu00a0XR for any reason and not to resume LAMICTALu00a0XR without consulting their healthcare providers.
  • Aseptic Meningitis
  • Inform patients that LAMICTAL XR may cause aseptic meningitis. Instruct them to notify their healthcare providers immediately if they develop signs and symptoms of meningitis such as headache, fever, nausea, vomiting, stiff neck, rash, abnormal sensitivity to light, myalgia, chills, confusion, or drowsiness while taking LAMICTAL XR.
  • Potential Medication Errors
  • To avoid a medication error of using the wrong drug or formulation, strongly advise patients to visually inspect their tablets to verify that they are LAMICTALu00a0XR each time they fill their prescription . Refer the patient to the Medication Guide that provides depictions of the LAMICTAL XR extended-release tablets.
  • LAMICTAL XR is a trademark owned by or licensed to the GSK group of companies. The other brand listed is a trademark owned by or licensed to its owner and is not owned by or licensed to the GSK group of companies. The maker of this brand is not affiliated with and does not endorse the GSK group of companies or its products.
  • GlaxoSmithKline
  • Research Triangle Park, NC 27709
  • u00a92019 GSK group of companies or its licensor.
  • LXR:23PI
  • No data
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0754-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED-RELEASE TABLETS
  • Arrayn- 25 mg
  • Once A Day
  • R only
  • CAUTION: Verify Product Dispensed
  • 30 Tablets
  • Dispense the accompanying Medication Guide to each patient. u00a0
  • See prescribing information for dosage information.
  • Do not use if printed safety seal under cap is broken or missing.
  • Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F) [see USP Controlled Room Temperature].
  • GlaxoSmithKline
  • RTP, NC 27709
  • Made in India
  • Rev. 5/17
  • 10000000146294
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0755-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED-RELEASE TABLETS
  • Arrayn- 50 mg
  • Once A Day
  • R only
  • CAUTION: Verify Product Dispensed
  • 30 tablets
  • Dispense the accompanying Medication Guide to each patient.
  • See prescribing information for dosage information.
  • Do not use if printed safety seal under cap is broken or missing.
  • Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F) [see USP Controlled Room Temperature].
  • GlaxoSmithKline
  • RTP, NC 27709
  • Made in India
  • Rev. 5/17
  • 10000000146295
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0756-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED-RELEASE TABLETS
  • Arrayn- 100 mg
  • Once A Day
  • R only
  • CAUTION: Verify Product Dispensed
  • 30 tablets
  • Dispense the accompanying Medication Guide to each patient.
  • See prescribing information for dosage information.
  • Do not use if printed safety seal under cap is broken or missing.
  • Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F) [see USP Controlled Room Temperature].
  • GlaxoSmithKline
  • RTP, NC 27709
  • Made in India
  • Rev. 4/17
  • 10000000146292
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0757-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED-RELEASE TABLETS
  • Arrayn- 200 mg
  • Once A Day
  • R only
  • CAUTION: Verify Product Dispensed
  • 30 tablets
  • Dispense the accompanying Medication Guide to each patient.
  • See prescribing information for dosage information.
  • Do not use if printed safety seal under cap is broken or missing.
  • Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F) [see USP Controlled Room Temperature].
  • GlaxoSmithKline
  • RTP, NC 27709
  • Made in India
  • Rev. 4/17
  • 10000000146293
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0781-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED- RELEASE TABLETS
  • Arrayn- 250 mg
  • Once A Day
  • R only
  • CAUTION: Verify Product Dispensed
  • 30 tablets
  • Dispense the accompanying Medication Guide to each patient.
  • See prescribing information for dosage information.
  • Do not use if printed safety seal under cap is broken or missing.
  • Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F) [see USP Controlled Room Temperature].
  • GlaxoSmithKline
  • RTP, NC 27709
  • Made in India
  • Rev. 4/17
  • 10000000146235
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0761-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED- RELEASE TABLETS
  • Arrayn- 300 mg
  • Once A Day
  • R only
  • CAUTION: Verify Product Dispensed
  • 30 tablets
  • Dispense the accompanying Medication Guide to each patient.
  • See prescribing information for dosage information.
  • Do not use if printed safety seal under cap is broken or missing.
  • Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F) [see USP Controlled Room Temperature].
  • GlaxoSmithKline
  • RTP, NC 27709
  • Made in India
  • Rev. 5/17
  • 10000000146291
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0758-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED-RELEASE TABLETS
  • R only
  • For patients TAKING valproaten
  • PATIENT TITRATION KIT:
  • 21
  • Each tablet contains 25 mg of lamotrigine
  • 7
  • Each tablet contains 50 mg of lamotrigine
  • Please check with your physician about proper maintenance dose before week 5.
  • Dispense the accompanying Medication Guide to each patient.
  • CAUTION: Verify Product Dispensed
  • GlaxoSmithKline
  • Research Triangle Park, NC 27709
  • Made in India
  • u00a92017 the GSK group of companies
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0759-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED-RELEASE TABLETS
  • R only
  • For patients TAKING carbamazepine, phenytoin, phenobarbital, or primidone and NOT TAKING valproaten
  • PATIENT TITRATION KIT:
  • 14
  • Each tablet contains 50 mg of lamotrigine
  • 14
  • Each tablet contains 100 mg of lamotrigine
  • 7
  • Each tablet contains 200 mg of lamotrigine
  • Please check with your physician about proper maintenance dose before week 5.
  • Dispense the accompanying Medication Guide to each patient.
  • CAUTION: Verify Product Dispensed
  • Made in India
  • u00a92017 the GSK group of companies
  • PRINCIPAL DISPLAY PANEL
  • NDC 0173-0760-00
  • LAMICTAL XRn
  • (LAMOTRIGINE)
  • EXTENDED-RELEASE TABLETS
  • R only
  • For patients NOT TAKING carbamazepine, phenytoin, phenobarbital, primidone, or valproaten
  • PATIENT TITRATION KIT:
  • 14 25-mg Tablets
  • Each tablet contains 25 mg of lamotrigine
  • 14 50-mg Tablets
  • Each tablet contains 50 mg of lamotrigine
  • 7 100-mg Tablets
  • Each tablet contains 100 mg of lamotrigine
  • Please check with your physician about proper maintenance dose before week 5.
  • Dispense the accompanying Medication Guide to each patient.
  • CAUTION: Verify Product Dispensed
  • Made in India
  • u00a92017 the GSK group of companies

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.